Department of Pharmacology & Chemical Biology at the University of Pittsburgh
Patrick J. Pagano, PhD
Professor & Vice Chair, Graduate Education
Director, Molecular Pharmacology Graduate Program
E1247 Thomas E. Starl Biomedical Science Tower
200 Lothop Street, Pittsburgh, PA 15213

Phone: 412-383-6505


BA (Chemistry), Harpur College, SUNY at Binghamton, 1985
MSc (Pharmacology), New York Medical College, 1988
PhD (Pharmacology), New York Medical College, 1991

Research Areas
Pharmacology of Cell and Organ Systems
Drug Discovery
Signal Transduction
Redox Pharmacology
Cardiac Pharmacology
Photo of Patrick J. Pagano, PhD

Link:  Translational Program Project / Vascular Sub-Phenotypes of Lung Disease 

Dr. Pagano’s research focuses on the modulatory role of the adventitia in vascular function and structure under both physiological and pathophysiological conditions. Dr. Pagano’s laboratory was among the first to identify a non-phagocytic NADPH oxidase in the vascular wall, demonstrating a critical role for essential subunit p67phox in its activity. He subsequently cloned vascular p67phox and illustrated its potent activation at the mRNA and protein level in response to the potent pro-hypertensive hormone angiotensin II. Stemming from these early discoveries, Dr. Pagano was the first to develop specific cell- and tissue-permeant peptidic and adenoviral inhibitor of NADPH oxidase, which is widely considered the most specific NADPH oxidase inhibitor available. These and his other more recently developed inhibitors of novel isoforms of NADPH oxidase are expected to provide a platform for the development of new therapies aimed at treating hypertension and other cardiovascular diseases. Moreover, Dr. Pagano is broadly recognized for his pioneering work examining the role of adventitia-derived reactive oxygen species (ROS) and, in particular, superoxide anion and hydrogen peroxide in the modulation of vascular tone, inflammation, and remodeling.


Important Publications
Ardanaz N, XP Yang, ME Cifuentes, MJ Haurani, KW Jackson, T Liao and PJ Pagano.  Lack of glutathione peroxidase 1 accelerates cardiac-specific hypertrophy and dysfunction in angiotensin II hypertension.  Hypertension 55:116-123, 2010.
Haurani MJ, ME Cifuentes, AD Shepard and PJ Pagano.  Nox4 oxidase overexpression specifically decreases endogenous Nox4 mRNA and inhibits angiotensin II-induced adventitial myofibroblast migration.  Hypertension 52:143-149, 2008.
Dourron, H.M., G.M. Jacobson, J.L. Park, J. Liu, D.J. Reddy, M.L. Scheel, and P.J. Pagano. Perivascular gene transfer of an NADPH oxidase inhibitor suppresses angioplasty-induced neointimal proliferation of rat carotid artery. Am. J. Physiol. Heart Circ. Physiol. 288: H946-H953, 2005.
Liu, J., A. Ormsby, N. Oja-Tebbe, and P.J. Pagano. Gene transfer of NAD(P)H oxidase inhibitor to the vascular adventitia attenuates medial smooth muscle hypertrophy. Circ. Res. 95: 587-594, 2004.
Rey, F.E., X.-C. Li, O.A. Carretero, J.L. Garvin, and P.J. Pagano. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation. Role of gp91phox . Circulation 106:2497-2502, 2002.
Rey, F.E., M.E. Cifuentes, A. Kiarash, M.T. Quinn, and P.J. Pagano. A novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O2 and systolic blood pressure in mice. Circ. Res. 89: 408-414, 2001.
Pagano PJ, SL Chanock, DA Siwik, WS Colucci and JK Clark.  Angiotensin  II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts.  Hypertension 32:331-337, 1998.
Pagano, P.J., J.K. Clark, M.E. Cifuentes-Pagano, S.M. Clark, G.M. Callis, and M.T. Quinn. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc. Natl. Acad. Sci. USA 94: 14483-14488, 1997.

Back to Top